Replies to post #16359 on Momenta Pharmaceuticals, Inc. (MNTA)

[Bickema]

Under this scenario, MNTA would receive few, if any, development-based milestone payments for M230.

I listened to the JPMorgan presentation again and you are correct, feel free to delete my post if you feel it adds confusion.